BioHarvest Sciences (BHST) Set to Announce Quarterly Earnings on Thursday

BioHarvest Sciences (NASDAQ:BHST) is expected to be announcing its Q3 2026 results before the market opens on Thursday, November 12th. Analysts expect BioHarvest Sciences to post earnings of ($0.16) per share and revenue of $9.31 million for the quarter. Individuals are encouraged to explore the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Thursday, November 12, 2026 at 8:00 AM ET.

BioHarvest Sciences (NASDAQ:BHST) last issued its quarterly earnings data on Monday, August 10th. The company reported ($0.17) EPS for the quarter, missing the consensus estimate of ($0.13) by ($0.04). The business had revenue of $8.84 million during the quarter, compared to analyst estimates of $9.45 million. BioHarvest Sciences had a negative net margin of 31.21% and a negative return on equity of 58.30%. On average, analysts expect BioHarvest Sciences to post ($0.58) EPS for the current fiscal year and ($0.42) EPS for the next fiscal year.

BioHarvest Sciences Price Performance

Shares of BHST stock opened at $1.46 on Thursday. The company has a market cap of $28.65 million, a price-to-earnings ratio of -2.81 and a beta of 0.93. The stock has a 50 day simple moving average of $1.67 and a 200-day simple moving average of $3.20. BioHarvest Sciences has a 1-year low of $1.37 and a 1-year high of $9.25.

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on the stock. Maxim Group dropped their price target on shares of BioHarvest Sciences from $12.00 to $5.00 and set a “buy” rating on the stock in a research note on Wednesday, August 12th. Weiss Ratings restated a “sell (d-)” rating on shares of BioHarvest Sciences in a research report on Monday, September 14th. Finally, Roth Capital decreased their price objective on shares of BioHarvest Sciences from $10.00 to $8.00 and set a “buy” rating on the stock in a report on Wednesday, August 12th. Two analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company has an average rating of “Hold” and a consensus price target of $6.50.

About BioHarvest Sciences

BioHarvest Sciences Inc is a biotechnology company developing health and wellness products through its proprietary Botanical Synthesis technology. The platform is designed to produce plant-based compounds in controlled environments without relying on conventional agricultural cultivation of the whole plant, with the goal of preserving targeted botanical molecules and improving production consistency.

The company’s primary commercial product is VINIA, a dietary supplement made from a proprietary red grape cell culture and marketed for its polyphenol content and potential cardiovascular and general wellness benefits.